February 2026– date –

1. Why “Cell & Gene Therapy × AI” Is Both Difficult and Important In Part 6, we focus on cell therapies (e.g., CAR-T, TCR-T) and gene therapies (e.g., AAV or lentiviral vectors). Compared with small molecules, antibodies, or RNA ther...

Introduction: How Might Aging Drugs Transform Cancer Medicine? In Extra Edition Part 1, we defined what we mean by “anti-aging drugs” and reviewed key mechanisms such as mTOR, senolytics, NAD⁺, and reprogramming. In Part 2, we surveyed t...

Introduction: Aging Is Becoming an Industry In Extra Edition Part 1, we introduced the concept of “anti-aging drugs” by looking at major mechanisms such as mTOR, metformin, senolytics, NAD⁺, and cellular reprogramming. We focused on how ...

In the beginner edition, we focused on why the “other 98%” of DNA (non-coding regions) is hard to interpret and why genome AI should be framed as hypothesis generation and prioritization, not as an “answer machine.” This Expert Edition g...

Introduction: Why Are “Anti-Aging Drugs” a Hot Topic Now? When you hear “anti-aging drugs” or “rejuvenation pills,” you might imagine dubious supplements or flashy beauty ads. However, what many academic groups, pharmaceutical companies,...

When people hear “genome analysis,” they often imagine a simple story: read DNA, find a mutation, and explain a disease. In reality, the deeper we read, the more often we hit a frustrating wall: we can detect many variants, but we can’t ...